ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "FCS: Enhancing the Diagnosis "
Episode Synopsis
CME credits: 1.00
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
Valid until: 30-05-2026
Claim your CME credit at https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/
There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.
In God we trust